Tourmaline Bio Agrees To Be Acquired By Novartis In $1.4 Bln Deal; Stock Up

Novartis AG has agreed to acquire Tourmaline Bio Inc. for $48.00 per share in cash, totaling approximately $1.4 billion in equity value. This represents a 59% premium over Tourmaline's closing stock price on September 8, 2025, prompting a significant surge in TRML's shares, which gained 12.86% in regular trading and an additional 17.59% after-hours. The transaction, unanimously approved by both Boards of Directors, is anticipated to close in the fourth quarter of 2025 via a tender offer.

Analysis

Novartis AG has entered into a definitive agreement to acquire Tourmaline Bio Inc. in an all-cash transaction valued at approximately $1.4 billion. The offer price of $48.00 per share represents a substantial 59% premium to Tourmaline's closing stock price on September 8, 2025, signaling a strong valuation by the acquirer. This announcement catalyzed significant upward movement in Tourmaline's stock (TRML), which closed the regular session up 12.86% at $30.18 and subsequently gained another 17.59% in after-hours trading. The deal, structured as a tender offer, has received unanimous approval from the boards of both companies, indicating a high probability of completion. The transaction is expected to close in the fourth quarter of 2025, subject to customary conditions, leaving a notable time gap that is reflected in the arbitrage spread between the current trading price and the final offer price.

Key Decisions for Investors

• Investors holding Tourmaline Bio (TRML) should recognize that upside is now effectively capped at the $48.00 per share cash offer, transforming the investment thesis from a growth story into a merger arbitrage play.
• The decision to hold TRML until the transaction's expected close in Q4 2025 versus selling at the current market price involves weighing the remaining price spread against the time cost of capital and the minimal, but present, risk of deal failure.
• For Novartis (NVS) investors, this $1.4 billion acquisition represents a strategic deployment of capital to acquire biotech assets, but the provided information is insufficient to determine the deal's immediate impact on Novartis's financial performance or growth outlook.